Immune checkpoint inhibitors (Box1) have revolutionized the clinical management of multiple cancer types, including (but not limited to) melanoma [1], non-small cell lung carcinoma (NSCLC) [2], and head and neck squamous cell carcinoma (HNSCC) [3]. However, even in oncological settings in w...
doi:10.1056/NEJMoa1500596 CrossrefView in ScopusGoogle Scholar 9 A. Oaknin, A.V. Tinker, L. Gilbert Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phas...
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. N Engl J Med. 2023;388(23):2159–2170. doi: 10.1056/NEJMoa2302312 17. •Mirza MR, Chase DM, Slomovitz BM, et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N Engl J Med. 2023;388(23):2145–2158. ...
et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018–2028 (2015). PubMed Google Scholar Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. http://dx.doi.org/10.1056/nejmoa1500596 (2015)....
In the NICHE-II trial (Chalabi et al, ESMO 2022) 72 of 107 patients (67%) with colon cancer obtained pathological complete response (pCR) after short course CPI. In patients with RC, Cercek et al (NEJM 2022) showed that 12 patients (100%) obtained pCR after 6 months of dostarlimab...
Emphasizing the significance of cancer-associated fibroblasts (CAFs), non-malignant yet pivotal players within the tumor microenvironment (TME), this review illuminates the role of inflammatory subtype (iCAF) as catalysts in cancer proliferation, metasta
Blank, C. U. et al. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma.N. Engl. J. Med.https://doi.org/10.1056/NEJMoa2402604(2024). ArticlePubMedGoogle Scholar Chalabi, M. et al. Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer.N. Engl....
doi:10.1056/NEJMoa2206834 (Open in a new window)PubMed (Open in a new window)Web of Science ®(Open in a new window)Google Scholar Liu J, Wang Y, Mu C, et al. Pancreatic tumor eradication via selective Pin1 inhibition in cancer-associated fibroblasts and T lymphocytes engagement. ...
Pembro is a PD-1 blocking antibody approved for the treatment of advanced metastatic or unresectable melanoma and has demonstrated superiority over the CTLA-4-blocking antibody ipilimumab in patients with stage III or IV melanoma (Robert et al. NEJM 2015). Both drugs have tolerable and non-...
pre-neoplastic, viral-induced disease who received 3-4 vaccinations of a mix of HPV peptides derived from the viral oncogenes E6 and E7 maintained a complete response for ≥24 months (Kenter et a, Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia NEJM 361:1838 (2009)...